Gloria Ravegnini

A. Positions and Honors. List in chronological order previous positions, concluding with your present position. List any honors. 09/2009-12/2010: Graduate Research Fellow, Department of Pharmacology, University of Bologna 10/2011-05/2013: Visiting scientist, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, US. 01/2011-12/2013: PhD candidate, Laboratory of Toxicogenetics and Toxicogenomics, Department of Pharmacy and Biotechnology, University of Bologna 01/2014-07/2020: Postdoctoral Fellow, Laboratory of Pharmacogenetics and Pharmacogenomics, Department of Pharmacy and Biotechnology, University of Bologna. 06/2018: L’Oreal-UNESCO For Women in Science Award 06/2020: Fulbright Award 20-21 08/2020-07/2023: Junior Assistant Professor (RTDA), Laboratory of Pharmacogenetics and Pharmacogenomics, Department of Pharmacy and Biotechnology, University of Bologna. 08/2023-Today: Senior Assistant Professor (RTDB), Laboratory of Pharmacogenetics and Pharmacogenomics, Department of Pharmacy and Biotechnology, University of Bologna. B. Selected peer-reviewed publications (Selected from 87 peer-reviewed publications). Most relevant to the current application 1. Angelini S, Soverini S, Ravegnini G, Barnett M, Turrini E, Thornquist M, et al. Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. Haematologica, 98(2):193-00, 2013. 2. Ravegnini G, Mariño-Enriquez A, Slater J, Eilers G, Wang Y, Zhu M, et al. MED12 mutations in Leiomyosarcoma and extrauterine Leiomyoma, Mod Pathol, 26(5):743-49, 2013. 3. Serrano C, Wang YX, Mariño-Enríquez A, Lee JC, Ravegnini G, Morgan JA, et al. KRAS and KIT gatekeeper mutations confer polyclonal primary imatinib resistance in GIST: relevance of concomitant PI3K/AKT dysregulation. J Clin Oncol, 1;33(22):e93-6, 2015. 4. Ravegnini G, Zolezzi Moraga JM, Maffei F, Musti M, Zenesini C, Simeon V, et al. Simultaneous analysis of SEPT9 promoter methylation status, micronuclei frequency, and folate-related gene polymorphisms: the potential for a novel blood-based colorectal cancer biomarker. Int J Mol Sci, 16(12):28486-497, 2015. 5. Pantaleo MA*, Ravegnini G*, Astolfi A, Simeon V, Nannini M, Saponara M, et al. Integrating miRNA and gene expression profiling analysis revealed regulatory networks in gastrointestinal stromal tumors. Epigenomics, 8(10):1347-66, 2016. 6. Ravegnini G, Nannini M, Zanesini C, Simeon V, Sammarini G, Urbini M, et al. An exploratory association of polymorphisms in angiogenesis-related genes with susceptibility, clinical response and toxicity in gastrointestinal stromal tumors receiving sunitinib after imatinib failure. Angiogenesis, 20(1):139-48, 2017. 7. Ravegnini G, Sammarini G, Nannini M, Pantaleo MA, Biasco G, Hrelia P, Angelini S. Gastrointestinal stromal tumors (GIST): facing cell death between autophagy and apoptosis. Autophagy, 13(3):452-63, 2017. 8. Pantaleo MA, Urbini M, Indio V, Ravegnini G, Nannini M, De Luca M, et al. Genome-Wide analysis identifies MEN1 and MAX mutations and a neuroendocrine-like molecular heterogeneity in quadruple WT GIST. Mol Cancer Res, 15(5):553-62, 2017 9. Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, et al. Integrative molecular characterization of Malignant Pleural Mesothelioma. Cancer Discov, 8(12):1548-65, 2018. 10. Ravegnini G, Urbini M, Simeon V, Genovese C, Astolfi A, Nannini M, et al. An exploratory study by DMET array identifies a germline signature associated with imatinib response in gastrointestinal stromal tumor. Pharmacogenomics J, 19(4):390-400, 2019. 11. Ricci R, Martini M, Ravegnini G, Cenci T, Milione M, Lanza P, et al. Preferential MGMT methylation could predispose a subset of KIT/PDGFRA-WT GISTs, including SDH-deficient ones, to respond to alkylating agents. Clin Epigenetics, 11(1):2, 2019 12. Ravegnini G, Serrano C, Simeon V, Sammarini G, Nannini M, Roversi E, Urbini M, Ferrè F, Ricci R, Tarantino G, Pantaleo MA, Hrelia P, Angelini S. The rs17084733 variant in the KIT 3’ UTR disrupts a miR-221/222 binding site in gastrointestinal stromal tumor: a sponge-like mechanism conferring disease susceptibility, Epigenetics, 14(6):545- 557, 2019. 13. Ravegnini G, Cargnin S, Sammarini G, Zanotti F, Lorenzo JM, Hrelia P, et al. Prognostic role of miR-221 and miR-222 expression in cancer patients: a systematic review and meta-analysis. Cancers, 11(7), 2019. 14. Ravegnini G, Sammarini G, Serrano C, Nannini M, Pantaleo MA, Hrelia P, et al. Clinical relevance of circulating molecules in cancer: focus on gastrointestinal stromal tumor (GIST). Ther Adv Med Oncol, Mar 1;11, 2019. 15. Indio V*, Ravegnini G*, Astolfi A, Urbini M, et al. Gene expression profiling of PDGFRA mutant GISTs reveals immune signatures as a specific fingerprint of D842V exon 18 mutation. Frontiers in Immunology, 2;11:851, 2020 C. Research Support. List selected ongoing or completed (during the last three years) research projects (federal and non-federal support). 1. Characterization of extracellular nicotinamide phosphoribosyltransferase (eNAMPT) as a novel pharmacological target in ovarian cancer. Duration: 10/2023-10/2025; Role: PI; Funding Source: PRIN 2022 2. Deciphering DNA damage repair-related vulnerabilities in leiomyosarcoma (CHIMERA), Duration: 01/2024- 01/2026; Role: PI; Funding Source: Berlucchi Foundation 3. RNA National Center for Gene Therapy and Drugs based on RNA Technology , Spoke N. 1 - Genetic Diseases; Duration: 10/2022-10/2025; Role: Local PI; Funding Source: PNRR 4. Identifying DNA damage repair-related vulnerabilities in leiomyosarcoma; Duration: 07/2022-07/2023; Role: Key Personnel; Funding Source: Sarcoma Foundation of America (SFA)